Melflufen for multiple myeloma: a promise unfulfilled?
Mené sur 246 patients atteints d'un myélome multiple récidivant ou réfractaire au lénalidomide (âge médian : 68 ans), cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du melflufen et du pomalidomide, en combinaison avec la dexaméthasone
The accelerated approval of melflufen in combination with dexamethasone by the USFood and Drug Administration in February, 2021, for triple-class refractory multiplemyeloma, following at least four previous lines of therapy, was acknowledged withambivalence. There was both enthusiasm for access to yet another drug for a malignancywithout a known cure, and scepticism due to modest activity.
The Lancet Haematology , commentaire, 2021